Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 1/20 | 0.76 |
| ▸ | PIK3CA | P42336 | 15/20 | 0.55 |
| ▸ | MTOR | P42345 | 4/20 | 0.39 |
| ▸ | RPTOR | Q8N122 | 3/20 | 0.39 |
| ▸ | MLST8 | Q9BVC4 | 3/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20552586 | 0.95 | PRKDC (0.77) | PRKDCPIK3CAMTORRPTORMLST8 | |
| SCHEMBL25064464 | 0.92 | PRKDC (0.65) | PRKDCPIK3CAMTORRPTORMLST8 | |
| SCHEMBL29669774 | 0.92 | PRKDC (0.72) | PRKDCPIK3CAMTORRPTORMLST8 | |
| SCHEMBL23157880 | 0.92 | PRKDC (0.72) | PRKDCPIK3CAMTORRPTORMLST8 | |
| SCHEMBL23157879 | 0.91 | PRKDC (0.81) | PRKDCPIK3CAMTORCREBBP | |
| SCHEMBL30405363 | 0.91 | PRKDC (0.81) | PRKDCPIK3CAMTORCREBBP | |
| SCHEMBL3756845 | 0.90 | PRKDC (0.85) | PRKDCPIK3CAMTORCREBBP | |
| SCHEMBL3755977 | 0.89 | PRKDC (0.84) | PRKDCPIK3CAMTORCREBBP | |
| SCHEMBL24519395 | 0.89 | PRKDC (0.68) | PRKDCPIK3CAMTORRPTORMLST8 | |
| SCHEMBL23251695 | 0.88 | PRKDC (0.66) | PRKDCPIK3CAMTORRPTORMLST8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11364300-B2 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | Revolution Medicines, Inc. (US) | 2022-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11364300-B2 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | MTOR, RICTOR, RPTOR | PRKDC 1510/4885PIK3CA 60/4885MTOR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.